SLC5A2 and chronic kidney disease: Subgroup analyses from a recent meta-analysis confirmed that the cardiovascular and kidney protective effects of SGLT-2 inhibitors were consistently observed in patients with CKD and an eGFR ≤60 mL/min/1.73 m2 (85).